Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Department of Health Services Research, Management and Policy, University of Florida College of Public Health and Health Professions, Gainesville, Florida, USA.
Obesity (Silver Spring). 2024 Dec;32(12):2246-2254. doi: 10.1002/oby.24169. Epub 2024 Oct 30.
The objective of this study was to describe weight changes in members of a large-scale telehealth obesity-treatment provider who were using antiobesity medications (AOMs).
This retrospective observational study analyzed real-world data from adults who initiated AOM treatment with the WeightWatchers (WW) Clinic telehealth program between January 2022 and July 2023 (n = 53,590). The main outcomes were changes in body weight over 12 months, side effects over follow-up, and medication usage patterns.
The 53,590 patients who initiated treatment were predominantly female (88.6%), with a mean BMI of 36.9 kg/m. Mean (SD) treatment duration was 5.3 (4.3) months. Program retention rates based on the number of patients whose time from enrollment was at least 3, 6, 9, and 12 months were 78% (n = 39,907/51,247), 63% (n = 25,515/40,203), 58% (n = 15,472/26,794), and 77% (n = 6459/8394), respectively. Average weight loss was 8.9% at 3 months (n = 37,565), 14.1% at 6 months (n = 24,140), 17.7% at 9 months (n = 15,169), and 19.4% at 12 months (n = 6089). Glucagon-like peptide-1 receptor agonist (GLP-1-RA)-based treatments were predominant. Side effects were consistent with the classes of medications used, and frequency declined over time.
This real-world analysis of a telehealth-delivered obesity-treatment program demonstrated outcomes consistent with recent phase 3 clinical trials of AOMs, suggesting generalizability beyond clinical trial and in-person settings.
本研究旨在描述在使用抗肥胖药物（AOM）的大型远程医疗肥胖治疗提供者中，成员的体重变化。
这是一项回顾性观察性研究，分析了 2022 年 1 月至 2023 年 7 月期间使用 WeightWatchers（WW）诊所远程医疗计划开始 AOM 治疗的成年人的真实世界数据（n=53590）。主要结局是 12 个月内体重变化、随访期间的副作用和药物使用模式。
开始治疗的 53590 名患者主要为女性（88.6%），平均 BMI 为 36.9kg/m。平均（SD）治疗持续时间为 5.3（4.3）个月。基于至少有 3、6、9 和 12 个月的患者入组时间的患者人数，保留率分别为 78%（n=39907/51247）、63%（n=25515/40203）、58%（n=15472/26794）和 77%（n=6459/8394）。3 个月时的平均减重为 8.9%（n=37565），6 个月时为 14.1%（n=24140），9 个月时为 17.7%（n=15169），12 个月时为 19.4%（n=6089）。基于胰高血糖素样肽-1 受体激动剂（GLP-1-RA）的治疗占主导地位。副作用与所用药物类别一致，且随时间推移而减少。
这项远程医疗肥胖治疗计划的真实世界分析结果与最近的 AOM 三期临床试验一致，表明其具有超出临床试验和面对面环境的普遍性。
